Activest Wealth Management Lowers Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Activest Wealth Management cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 66.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 135 shares of the medical research company’s stock after selling 265 shares during the quarter. Activest Wealth Management’s holdings in IQVIA were worth $27,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. FMR LLC boosted its stake in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the period. JPMorgan Chase & Co. boosted its position in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Impax Asset Management Group plc grew its stake in IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after acquiring an additional 157,809 shares in the last quarter. Nordea Investment Management AB lifted its stake in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of IQVIA by 3.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock valued at $290,545,000 after purchasing an additional 39,772 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at IQVIA

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was bought at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now directly owns 1,275 shares in the company, valued at $255,739.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on IQV. UBS Group decreased their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday. Bank of America decreased their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Morgan Stanley reduced their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Finally, Stephens began coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price on the stock. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $252.39.

IQVIA Trading Down 0.9 %

Shares of IQV opened at $208.13 on Monday. The firm has a market capitalization of $37.78 billion, a price-to-earnings ratio of 27.75, a PEG ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a 50-day moving average of $200.67 and a 200 day moving average of $219.40.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts expect that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.